Novel targets for vaccines against tuberculosis

Information

  • Research Project
  • 6859051
  • ApplicationId
    6859051
  • Core Project Number
    R21AI063359
  • Full Project Number
    1R21AI063359-01
  • Serial Number
    63359
  • FOA Number
    PA-03-80
  • Sub Project Id
  • Project Start Date
    8/15/2005 - 18 years ago
  • Project End Date
    7/31/2007 - 16 years ago
  • Program Officer Name
    JACOBS, GAIL G.
  • Budget Start Date
    8/15/2005 - 18 years ago
  • Budget End Date
    7/31/2006 - 17 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/10/2005 - 18 years ago

Novel targets for vaccines against tuberculosis

[unreadable] DESCRIPTION (provided by applicant): We have obtained evidence that in humans the profile of antigen-specific immune responses associated with active disease differs from that observed with latent infection. HLA-A2-restricted, Th1-type cytotoxic T lymphocyte responses against mycobacterial alanine dehydrogenase and glutamine synthetase can be detected only in non-vaccinated, tuberculin skin test-positive asymptomatic individuals but not in active tuberculosis patients. In the mouse lung, Th1 immunity is the principal cause for changes in the Mycobacterium tuberculosis growth from exponential to non-replicating persistence during infection. The shift in bacterial growth in response to Th1 immunity is accompanied by changes in the transcription pattern of immunodominant bacterial proteins. These data imply that some similarities may exist between antigenic profiles expressed by M. tuberculosis in human and mouse infections. We propose that T cell responses elicited against alanine dehydrogenase and glutamine synthetase are protective. Additionally, vaccination against these bacterial proteins expressed during chronic infection in mouse lung may be more effective than vaccination against other targets expressed predominantly at initial phase of infection. This hypothesis will be tested in a low-dose aerosol infection model employing mice transgenic for human HLA-A2 allele. The timing of expression of these bacterial proteins relative to the onset of Th1 immunity, and the kinetics of expression of antigen-specific T cell responses will be characterized during infection with M. tuberculosis. The protective potential of T cell-mediated immune responses against these proteins will be determined in DNA vaccinated and challenged mice. Finally, the molecular targets of polyclonal cytotoxic T lymphocyte responses elicited by DNA vaccines against the whole protein will be identified in challenged mice. This knowledge is expected to open a new approach in designs of vaccines against M. tuberculosis. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R21
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    233400
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:233400\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PUBLIC HEALTH RESEARCH INSTITUTE
  • Organization Department
  • Organization DUNS
  • Organization City
    NEWARK
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    071033535
  • Organization District
    UNITED STATES